Genotypic, Phenotypic and Clinical Validation of GeneXpert in Extra-Pulmonary and Pulmonary Tuberculosis in India

• Published in: PloS one Vol. 11; no. 2; p. e0149258
• Main Authors: Singh, Urvashi B, Pandey, Pooja, Mehta, Girija, Bhatnagar, Anuj K, Mohan, Anant, Goyal, Vinay, Ahuja, Vineet, Ramachandran, Ranjani, Sachdeva, Kuldeep S, Samantaray, Jyotish C
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 19.02.2016; Public Library of Science (PLoS)
• Subjects: Adolescent; Adult; Antitubercular Agents - pharmacology; Assaying; Bacterial Load; Biology and Life Sciences; Biopsy; Demographic aspects; Deoxyribonucleic acid; Diagnosis; Diagnostic tests; DNA; Drug resistance; Drug Resistance, Bacterial; Female; Gene sequencing; Genetic aspects; Genetic testing; Genotype; HIV; Human immunodeficiency virus; Humans; India; Infections; Lymphatic system; Male; Medical diagnosis; Medicine and Health Sciences; Microbial Sensitivity Tests - methods; Microbial Sensitivity Tests - standards; Middle Aged; Mutation; Mycobacterium tuberculosis; Mycobacterium tuberculosis - drug effects; Mycobacterium tuberculosis - genetics; Patients; Phenotype; Prospective Studies; Pulmonary tuberculosis; Reference Standards; Reproducibility of Results; Rifampin; RpoB protein; Sensitivity; Sensitivity and Specificity; Sputum; Sputum - microbiology; Studies; Tuberculosis; Tuberculosis - diagnosis; Tuberculosis - microbiology; Tuberculosis, Pulmonary - diagnosis; Tuberculosis, Pulmonary - microbiology; Young Adult; India
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0149258

Newer molecular diagnostics have brought paradigm shift in early diagnosis of tuberculosis [TB]. WHO recommended use of GeneXpert MTB/RIF [Xpert] for Extra-pulmonary [EP] TB; critics have since questioned its efficiency. The present study was designed to assess the performance of GeneXpert in 761 extra-pulmonary and 384 pulmonary specimens from patients clinically suspected of TB and compare with Phenotypic, Genotypic and Composite reference standards [CRS]. Comparison of GeneXpert results to CRS, demonstrated sensitivity of 100% and 90.68%, specificity of 100% and 99.62% for pulmonary and extra-pulmonary samples. On comparison with culture, sensitivity for Rifampicin [Rif] resistance detection was 87.5% and 81.82% respectively, while specificity was 100% for both pulmonary and extra-pulmonary TB. On comparison to sequencing of rpoB gene [Rif resistance determining region, RRDR], sensitivity was respectively 93.33% and 90% while specificity was 100% in both pulmonary and extra-pulmonary TB. GeneXpert assay missed 533CCG mutation in one sputum and dual mutation [517 & 519] in one pus sample, detected by sequencing. Sequencing picked dual mutation [529, 530] in a sputum sample sensitive to Rif, demonstrating, not all RRDR mutations lead to resistance. Current study reports observations in a patient care setting in a high burden region, from a large collection of pulmonary and extra-pulmonary samples and puts to rest questions regarding sensitivity, specificity, detection of infrequent mutations and mutations responsible for low-level Rif resistance by GeneXpert. Improvements in the assay could offer further improvement in sensitivity of detection in different patient samples; nevertheless it may be difficult to improve sensitivity of Rif resistance detection if only one gene is targeted. Assay specificity was high both for TB detection and Rif resistance detection. Despite a few misses, the assay offers major boost to early diagnosis of TB and MDR-TB, in difficult to diagnose pauci-bacillary TB.